No description available.

No description available.

The mismatch repair system (MMR) is an important pathway for maintaining genome stability because it can remove the errors generated while the cell is replicating. If these errors are left uncorrected, they can lead to genomic mutations. Thus, the deficient mismatch repair system is associated with the development of sporadic cancers and degenerative diseases such as Lynch Syndrome. MMR involves a set of proteins including MutSα, MutLα, MutLβ, and MutLγ. MutSα and MutLα play a major role in MMR whereas MutLβ and MutLγ provide minor contributions to this pathway. Recent studies have suggested that MutLβ and MutLγ are involved in the triplet DNA repeat expansion pathway. Our study in Saccharomyces cerevisiae shows important preliminary data of Mlh3 in maintaining genomic stability. We studied its interactions with other proteins involved in the mismatch repair system. Interestingly, Mlh3 interactions with Msh3 and Pol 35 DV suggest that there is a predilection of MutSβ and MutLγ to work in the lagging strand. Additionally, Top1, Mlh3and Msh3our results have shown that these genetic interactions could lead to an increase in mistakes in the MMR pathway. Moreover, it could lead to the suggestion that they are also involved in another pathway such as transcription. Finally, we confirm the involvement of Mlh3 in the resolution of frameshift mutations in the His-7A locus. Even though they are interesting results is too early to make final conclusions. Further analysis needs to be done.

Maintaining genomic integrity is important for any organism. DNA mismatch repair (MMR) serves to correct errors that occur during DNA replication and recombination, such as unpaired bases or mismatched bases. Mutl is a key player and serves to coordinate protein-protein interactions. Recently it has been shown that human Mutl functions as an endonuclease and that this activity is imperative for functioning MMR. In this work, the X-ray crystal structure of the C-terminal endonuclease domain of Bacillus subtilis Mutl (BsMutL-CTD) is presented. Diffraction quality crystals of BsMutL-CTD were grown using vapor diffusion. The crystal structure of BsMutL-CTD was solved using multiwavelength anomalous diffraction. The structure reveals a putative metal binding site which clusters closely in space with endonuclease motif. Using the structure and sequence homology, several mutations were made and an investigation into the endonuclease activity of BsMutL was performed. BsMutL was confirmed to be a manganese-dependent endonuclease and key residues which contribute to endonuclease function were identified. / Thesis / Master of Science (MSc)

DNA mismatch repair (MMR) recognizes and repairs bases incorrectly incorporated during DNA replication. Germ line mutations in two MMR genes, namely hMSH2 and hMLHl, account for approximately 98% of hereditary non-polyposis colorectal cancers. There is conflicting evidence for the role of hMLHl and hMSH2 in the transcription-coupled repair (TCR) pathway of nucleotide excision repair (NER). Here we have examined the role of these MMR genes in NER using two reporter gene assays. AdHCMVlacZ is a replication-deficient recombinant adenovirus that expresses the B-galactosidase reporter gene under the control of the human cytomegalovirus (HCMV) immediate-early promoter. We have reported a reduced host cell reactivation (HCR) for B-galactosidase expression of UVC-irradiated AdHCMVlacZ in TCRdeficient Cockayne syndrome (CS) fibroblasts compared with normal fibroblasts, indicating that HCR depends, at least in part, on TCR. In addition, we have reported that UVC-enhanced expression of the undamaged reporter gene is induced at lower UVC fluences to cells and at higher levels after low UVC fluences in TCR-deficient compared with normal human fibroblasts, suggesting that persistent damage in active genes triggers increased activity f~om the HCMV-driven reporter construct. We have examined HCR and UV-enhanced expression of the reporter gene in hMLHl-deficient HCT116 human colon adenocarcinoma cells and HCT116-chr3 cells (the MMR-proficient counterpart of HCT116) as well as hMSH2-deficient LoVo human colon adenocarcinoma cells and their hMSH2-proficient counterpart SW 480 cells. We show a greater UV -enhanced expression of the undamaged reporter gene after low UVC exposure in HCT116 compared with HCT 116-chr3 cells ;md in Lo Vo compared with SW 480 cells. We show also a reduced HCR in HCT 116 compared with HCT 116-chr3 cells and in Lo Vo compared with SW 480 cells. However, the reduction in HCR was less or absent when cells were pretreated with UVC. These results suggest that detection of an involvement of hMLHl and hMSH2 in TCR is dependent on UVC (254 nm) fluence to cells. We have also used these two reporter gene assays to examine the role of hMSH2 and hMLHl in the repair of oxidative DNA damage induced by UV A light (335-400 nm) and H20 2• UV A and H20 2 produce a number of oxidative lesions in DNA (such as 8hydroxyguanines and thymine glycols) that are repaired by the base excision repair (BER) pathway. \ve show a reduced HCR for B-galactosidase expression of UVAtreated AdHCMVlccZ in hMSH2-deficient LoVo human colon adenocarcinoma cells compared to their hMSH2-proficient counterpart SW480 cells, but not in hMLHl-deficient HCT116 human colon adenocarcinoma cells compared to the hMLHl-proficient HCT116-chr3 cells. We also show that pre-treatment of cells with UVA enhances reporter gene expression to higher levels and at lower UV A fluences in Lo Vo compared to SW480 cells but not in HCT116 compared to HCT116-chr3 cells. These results suggest an involvement of hMSH2 but not hMLHl in the repair of UVA-induced oxidative DNA damage. In contrast, no detectable differences were observed between SW480 and LoVo cells, as well as HCT116-chr3 compared to HCT116 cells, in both of the reporter gene assays that used H20 2 as the DNA damaging agent. Based on these results, these findings suggest that neither hMSH2 nor hMLHl play a significant role in the repair of oxidative damage induced by H202. / Thesis / Master of Science (MS)

Yes / Temozolomide (TMZ) is the standard first line treatment for malignant glioma, reaching “blockbuster” status in 2010, yet it remains the only drug in its class. The main constraints on the clinical effectiveness of TMZ therapy are its requirement for active DNA mismatch repair (MMR) proteins for activity, and inherent resistance through O6-methyl guanine-DNA methyl transferase (MGMT) activity. Moreover, acquired resistance, due to MMR mutation, results in aggressive TMZ-resistant tumour regrowth following good initial responses. Much of the attraction in TMZ as a drug lies in its PK/PD properties: it is acid stable and has 100% oral bioavailability; it also has excellent distribution properties, crosses the blood-brain barrier, and there is direct evidence of tumour localisation. This review seeks to unravel some of the mysteries of the imidazotetrazine class of compounds to which TMZ belongs. In addition to an overview of different synthetic strategies, we explore the somewhat unusual chemical reactivity of the imidazotetrazines, probing their mechanisms of reaction, examining which attributes are required for an active drug molecule and reviewing the use of this combined knowledge towards the development of new and improved anti-cancer agents.

En génomique comparative, on considère classiquement trois forces déterminant l'évolution des séquences : la mutation, la sélection et la dérive génétique. Récemment, lors de l'étude de l'origine évolutive des variations de la composition en base des génomes, un quatrième agent a été identifié : la conversion génique biaisée (BGC). Le BGC est intimement lié à la recombinaison méiotique et semble présent chez la plupart des eucaryotes. Ce phénomène introduit une surreprésentation de certains allèles dans les produits méiotiques aboutissant à une augmentation de la fréquence de ces variants dans la population. Ce processus est capable de mimer et d'interférer avec la sélection naturelle. Il est donc important de le caractériser afin de pouvoir le distinguer efficacement de la sélection dans l'étude de l'adaptation à l'échelle moléculaire. C'est ce que nous nous attachons à faire dans le cadre de ce travail. Pour cela nous utilisons deux espèces modèles. Premièrement la levure Saccharomyces cerevisiae pour laquelle une carte de recombinaison haute résolution permettant l'analyse du processus de conversion, est disponible. L'étude approfondie de cette carte nous a permis de lever le voile sur les mécanismes moléculaires qui sous-tendent le BGC. Deuxièmement, grâce à des découvertes récentes sur la détermination des patrons de recombinaison via la protéine PRDM9 chez les mammifères, nous avons quantifié la dynamique et l'intensité de ce processus dans l'histoire évolutive récente de l'homme. Ces résultats nous ont permis de confirmer la place du BGC comme quatrième force d'évolution moléculaire, mais aussi de discuter de l'origine évolutive de ce phénomène / Usually, three main forces are considered when studying sequences evolution in comparative genomics : mutation, selection and genetic drift. Recently, a fourth process has been identified during the study of base composition landscapes in genomes : biased gene conversion (BGC). This phenomenon introduces an overrepresentation of certain alleles in meiosis products (gametes or spores) leading to an increase of the frequency of those variants in the population. Thus, it is able to mimic and interfere with natural selection. Hence, it is important to describe this phenomenon in order to be able to trustfully distinguish BGC and selection in the study of adaptation at the molecular scale. So, the main goal of this work is to analyze the molecular origin, the intensity and the dynamics of BGC. To do so, we use two model species. First, we use the yeast Saccharomyces cerevisiae because, for this specie, a high-resolution recombination map is available which allows a fine study of the conversion process. Analyzing this map led us to shed the light on the molecular mechanisms of BGC. Secondly, recent discoveries on the role of the PRDM9 protein in the determination of recombination landscapes in mammals allowed us to quantify the dynamics and intensity of BGC in the recent human history. Thanks to those two studies, we first confirmed that BGC is the fourth force of molecular evolution and we also provided hypotheses about the evolutionary origin of this process

Orientador: Carmen Silvia Bertuzzo / Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas / Made available in DSpace on 2018-08-23T16:42:29Z (GMT). No. of bitstreams: 1 Viana_DaniloVilela_D.pdf: 5689445 bytes, checksum: ecee0316f70f957068dbfd39107b9161 (MD5) Previous issue date: 2013 / Resumo: Há muito tempo reconhece-se a importância de fatores hereditários na oncogênese. Dentre os genes associados ao câncer, um importante grupo é formado por aqueles direta ou indiretamente relacionados ao reparo do DNA, entre os quais está um grupo de genes pertencentes ao sistema de reparo de erros de pareamento de bases do DNA (mismatch repair - MMR), do qual fazem parte hMLH1, hMSH2, hMSH6 e hPMS2. Quando mutações monoalélicas nesses genes são herdadas, elas são responsáveis pela síndrome de Lynch, que cursa com predisposição ao câncer de cólon e endométrio, entre outros, geralmente na terceira ou quarta década de vida. A ocorrência de câncer na infância ou de tumores hematológicos não é comum na síndrome de Lynch. Nos últimos anos, entretanto, foram relatados diversos casos de pacientes que, na primeira ou segunda década de vida, apresentam tumores de sistema nervoso central, gastrintestinais, hematológicos, alguns deles com manifestações cutâneas semelhantes à neurofibromatose tipo 1. Nesses pacientes, foram identificadas mutações bialélicas nos genes do sistema MMR. O presente estudo propôs-se a analisar os tecidos tumorais de uma série retrospectiva de pacientes de zero a 35 anos de idade (inclusive), com diagnóstico de câncer de sistema nervoso central, visando a identificação de pacientes com mutações bialélicas nos genes do sistema MMR e a caracterização de seu quadro clínico. Teve por objetivos específicos: identificar os casos com instabilidade de microssatélites (MSI); determinar a proporção de tumores instáveis e o genótipo para os genes do sistema MMR nos casos que foram instáveis; correlacionar as mutações encontradas com o fenótipo e história familial. Um total de 79 pacientes foram incluídos no estudo. O diagnóstico era de glioma em 42 e meduloblastoma em 37. Inicialmente foi realizada a pesquisa de MSI nos tumores de todos os pacientes, seguido de avaliação clínica e coleta de sangue para pesquisa de mutações deletérias nos genes do sistema MMR, naqueles que apresentavam instabilidade. Foi encontrada baixa MSI (MSI-L) em sete casos de glioma e oito casos de meduloblastoma. Esses pacientes foram convocados para avaliação quanto à história clínica, exame físico e história familial. Seis pacientes atenderam ao convite, foram avaliados e tiveram sequenciamento e pesquisa de deleções por meio da técnica de MLPA realizados para os genes hMLH1, hMSH2, hMSH6. Não foram encontradas mutações deletérias em nenhum desses indivíduos. Procedeu-se, ainda, a determinação do intervalo de variação quase monomórfico para a população estudada, após o qual, cinco dos pacientes com diagnóstico de meduloblastoma, originalmente classificados como MSI-L, foram reclassificados como sendo estáveis (MSS). No presente estudo demonstrou-se que 8,3% dos pacientes com diagnóstico de meduloblastoma e 17,5% daqueles com gliomas possuíam MSI-L. A correlação do genótipo com o fenótipo e história familial não pôde ser realizada, visto não terem sido encontradas mutações deletérias. Sugere-se que sejam realizados estudos adicionais, preferencialmente prospectivos, para estabelecer a frequência de mutações nos genes do sistema MMR em pacientes pediátricos e adultos jovens com tumores de sistema nervoso central e instabilidade de microssatélites, uma questão importante para o aconselhamento genético, e, possivelmente, para implantação de uma rotina de rastreamento com pesquisa de MSI nessa população de pacientes / Abstract: Lynch syndrome (LS) is an autosomal dominant hereditary cancer predisposition disorder characterized by early onset of cancer (mean age, approximately 40-45 years), especially edometrium and/or colorectal cancer in the absence of gastrointestinal polyposis, and which, in addition, shows increased frequency of carcinomas of the ovary, small intestine, ureter, renal pelvis, stomach, among others. Its molecular hallmark is a type of genetic instability known as miscrosattelite instability (MSI) that affects short sequences of DNA repeats (miscrosattelites) found throughout the genome, leading to accumulation of genetic alterations. In LS, Cancer predisposition is due almost exclusively to heterozygous germline mutations in one of the DNA MMR genes (hMSH2, hMLH1, hPMS1, hPMS2, and hMSH6). Childhood cancers and hematological neoplasia generally do not belong to the Lynch tumour spectrum. However, over the past few years there have been reports of children that have presented with the constellation of early onset gastrointestinal cancers, along with features of neurofibromatosis type-1 and/or hematologic malignancies, and/or neurological tumors due to homozygous mutations in the mismatch repair genes. The present study analyzed a retrospective series of central nervous system tissue from patients with 0 to 35 years of age, with the aim to identify biallelic mutations in MMR genes and characterization of its clinical tumor spectrum. The aims of this study were to analyze: the frequency of microsattelite instability in tumors; the genotype and the frequency of germline mutations in MMR genes in patients who had MSI; its correlation to the phenotype and family history. A total of 42 gliomas and 37 medulloblastomas were analyzed. Initially, they were screened for microsatellite instability (MSI), followed by clinical evaluation, family history taking and sequence analysis of DNA obtained from blood lymphocytes. Low MSI (MSI-L) was found in seven gliomas and eight meduloblastomas. These patients were invited for clinical examination, family history taking and blood drawing. Six attended the clinical evaluation and had their sequence analysis done for hMLH1, hMSH2, hMSH6. No deleterious mutations were found among these patients. In adition, the quasi-monomorphic variation range was determined for this population, a important step previously not investigated in Brazilian population, that showed that with the proper values for the target population, 5 from the original MSI-L medulloblastomas were reclassified as stable (MSS). In clonclusion, the present study showed that 8,3% of the medulloblastomas and 17,5% of gliomas had MSI-L. The correlation of the genotype with clinical characteristics and family history could not be done, as no deleterious mutations were found. It was suggestd that new prospective studies are necessary to properly address the issue of the frequency of biallelic mutations in pediatric and young adults patients with MSI-L tumors of the CNS / Doutorado / Genetica Medica / Doutor em Ciências Médicas

Vid cancerdiagnostisering av Lynch syndrom används immunohistokemisk färgning för undersökning av eventuell defekt hos mismatch repair-generna MLH1, MSH2, MSH6 och PMS2. Färgningen använder sig av antikroppar som undersöker om cellkärnor i vävnad har intakta eller förlorade proteinuttryck hos respektive gen. Syftet med studien var att utföra en antikroppsvalidering för att granska om de nuvarande Dako Link Ready-to-Use-antikropparna (Link RTU) och koncentrerade antikroppen Dako PMS2 1:40 kunde bytas ut till Dako Omnis Ready-to-Use-antikroppar (Omnis RTU). Omnis RTU-antikropparna är optimerade för det automatiserade analysinstrumentet Dako Omnis som används vid patologavdelning på Universitetssjukhuset Örebro. Tolv vävnader med colorektalcancer och två externa positiva kontroller färgades med samtliga antikroppar för respektive gen och en jämförelse mellan Link RTU samt Dako PMS2 1:40 gjordes mot Omnis RTU-antikropparna. De nya färgningarna med Omnis RTU bedömdes som sämre, likvärdig eller bättre infärgad. Om antikroppen färgade rätt målceller och med stark färgintensitet bedömdes den och motsvarande protokoll som godkänd. Resultatet visade att Omnis RTU för MLH1 gav en förbättrad färgning. Omnis RTU för MSH2 gav i majoritet en förbättrad färgning med något mer bakgrundsfärg än önskvärt. Omnis RTU för MSH6 gav en svagare infärgning i majoriteten av fallen och Omnis RTU för PMS2 gav i majoritet en förbättrad färgning, men med för mycket bakgrundsfärg. Slutsatsen var att Omnis RTU för MSH6 och PMS2 kräver vidare optimering av protokoll innan de används i laboratoriets rutinfärgning. Protokollet för Omnis RTU för MSH2 kan behöva en mindre justering för minskad bakgrundsfärg och Omnis RTU för MLH1 fungerar väl med det nuvarande protokollet. / Immunohistochemistry staining is used in diagnostics of Lynch Syndrome to investigate possible defects in the mismatch repair genes MLH1, MSH2, MSH6 and PMS2. Antibodies is used to examine whether cell nuclei in cancer tissue have intact or loss of protein expression in said genes. The aim of the study was to perform an antibody validation to examine if the current Dako Link Ready-to-Use antibodies (Link RTU) and the concentrated PMS2 antibody can be replaced with Dako Omnis Ready-to-Use antibodies (Omnis RTU) that are optimized for the analytical instrument Dako Omnis, which is used in Universitetssjukhuset Örebro. Twelve tissues with colorectal cancer and two external positive controls was stained with all antibodies for each gene. A comparison was done between the old antibodies and Omnis RTU, where Omnis RTU was judged to be worse, equivalent or better. The antibody and used protocol were approved of laboratory use if it stained the target cells with a strong intensity. The results showed that Omnis RTU MLH1 had an improved staining. Omnis RTU MSH2 had in majority an improved staining, but with slightly more background staining than preferred. Omnis RTU MSH6 had in majority a weak staining while Omnis RTU PMS2 had an improved staining but with too much background staining. The conclusion was that the protocols for Omnis RTU MSH6 and PMS2 needed further optimization before laboratory use. The protocol for Omnis RTU MSH2 may need a minor adjustment to reduce background staining, while Omnis RTU MLH1 works well with the current protocol.

No description available.